AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Antigen Express announces patent award, SBIR grant for Ii-suppression platform technology.(Small Business Innovative Research)(Brief Article)
2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Antigen Express, Inc., (AgExp) announced that the U.S. Patent and Trademark Office has issued to AgExp a new patent, U.S. Patent No. 6,368,855, concerning its Ii-Suppression Platform Technology. Additionally, AgExp has received a $292,000 phase I Small Business Innovative Research (SBIR) grant from the National Cancer Institute (NCI) to extend the patented work in the development of a MHC Class II based intratumoral gene therapy to produce an in vivo therapeutic cancer vaccine that elicits a robust helper T-cell anticancer response.
This patent strengthens the AgExp intellectual property portfolio, which includes five issued U.S. patents, two foreign patents, and additional patent applications both in the U.S. and abroad. U.S. 6,368,855 provides for composition of matter on molecular and genetic constructs that suppress Ii protein expression. The SBIR award is the third in a series of SBIR phase I grants totaling $664,000 that AgExp has received over an 18-month period to advance its Ii-Suppression Platform Technology into the clinic for the treatment of solid tumors.
AgExp scientists have shown that cancer cells are robust vaccines when they express MHC Class II molecules, and the Ii (invariant chain) immunoregulatory protein is suppressed. Many cancer cells express MHC Class II molecules, or they can be readily induced with interferon-(gamma) or the MHC Class II transactivator. Endogenously synthesized antigens, which are transported into the endoplasmic reticulum for binding to MHC ...
- MHC class I-restricted alloreactive CD4 T cells identified.
- Newspaper article from: Biotech Week July 7, 2004 700+ words
...NewsRx.com & NewsRx.net) -- A set of MHC class I-restricted alloreactive CD4 cells has been...recognize major histocompatibility complex (MHC) class II molecules, MHC class I-reactive CD4+ T cells have occasionally...
- Aberrant MHC class II expression not sufficient to induce thyroid autoimmunity.
- Newspaper article from: Biotech Week June 30, 2004 700+ words
...com & NewsRx.net) -- Aberrant MHC class II expression alone is not sufficient...of major histocompatibility complex (MHC) class II molecules on thyrocytes has been demonstrated...However, the role of this aberrant MHC class II in disease development is controversial...
- Ii-Key/MHC class II epitope hybrid peptide vaccines show promise for HIV.
- Newspaper article from: Health & Medicine Week January 26, 2004 700+ words
...com & NewsRx.net) -- Ii-Key/MHC class II epitope hybrid peptide vaccines show promise...research from the United States, "The Ii-Key/MHC class II epitope hybrid acts on MHC class II molecules to facilitate replacement of antigenic...
- HPV16-associated, MHC class I+ tumors more susceptible than class I- to...
- Newspaper article from: Virus Weekly April 8, 2003 700+ words
...effective in mice carrying HPV16-associated, MHC class I+ tumors than in those carrying and class...examined in mice carrying HPV16-associated, MHC class I+ (TC-1), and MHC class P (MK16) tumors. Intraperitoneal treatment...
- HPV16-associated, MHC class I+ tumors more susceptible than class I- to therapy.
- Newspaper article from: Vaccine Weekly April 9, 2003 700+ words
...effective in mice carrying HPV16-associated, MHC class I+ tumors than in those carrying and class...examined in mice carrying HPV16-associated, MHC class I+ (TC-1), and MHC class P (MK16) tumors. Intraperitoneal treatment...
- Exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
- Newspaper article from: Biotech Week April 28, 2004 700+ words
...derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells...eradication. Because DC can secrete MHC class I-bearing exosomes, we addressed whether...subserve the DC function consisting in MHC class I-restricted, peptide-specific CTL...
- E. coli expressing listeriolysin O promotes MHC class I antigen...
- Newspaper article from: Cancer Weekly January 14, 2003 700+ words
...was able to deliver an OVA epitope for MHC class I presentation in dendritic cells (DCs...b-restricted epitope SIINFEKL for MHC class I presentation. However, delivery of...superscript]b-restricted epitope for MHC class II presentation occurred when E. coli...
- E. coli expressing listeriolysin O promotes MHC class I antigen presentation.
- Newspaper article from: Immunotherapy Weekly January 15, 2003 700+ words
...was able to deliver an OVA epitope for MHC class I presentation in dendritic cells (DCs...b-restricted epitope SIINFEKL for MHC class I presentation. However, delivery of...superscript]b-restricted epitope for MHC class II presentation occurred when E. coli...
